Clinical trials are the main way that doctors are able to find better treatment for diseases like cancer. There are always many active clinical trials underway that are exploring possible new cancer treatments and ways to prevent or reduce side effects. In this podcast series, members of the Cancer.Net Editorial Board share their expert opinions about ongoing clinical trials that are studying genitourinary (GU) cancers.
In this podcast, Sumanta (Monty) Pal, MD, leads a discussion with Neeraj Agarwal, MD; Petros Grivas, MD, PhD; and Tian Zhang, MD, about 3 clinical trials that will be presented at the 2020 Genitourinary Cancers Symposium, which will take place February 13 to 15 in San Francisco, California.
The VISION phase III clinical trial is testing whether a new radiation particle treatment called 177Lutetium-PSMA-617 could help people with metastatic prostate cancer live longer. [4:47]
The INTACT phase III clinical trial is studying whether adding immunotherapy to bladder-preservation methods can help people with localized muscle-invasive bladder cancer live longer. [9:57]
The PROSPER phase III clinical trial aims to answer the question of whether adding immunotherapy before or after surgery for kidney cancer can slow down or prevent the disease from coming back or spreading to other parts of the body. [18:49]
Dr. Pal is co-director of City of Hope's Kidney Cancer Program, the head of the kidney and bladder cancer disease team at the institution, and the Cancer.Net Associate Editor for Genitourinary Cancers. Dr. Agarwal directs the Genitourinary Oncology Program at the Huntsman Cancer Institute at the University of Utah and is a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Grivas is the clinical director of the Genitourinary Cancers Program at University of Washington Medicine, an associate member of the clinical research division at the Fred Hutchinson Cancer Research Center, and a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Zhang is an assistant professor of medicine at Duke University School of Medicine, a medical oncologist at Duke Cancer Institute, and a Cancer.Net Specialty Editor for Genitourinary Cancers.
To read the individual study abstracts discussed in this podcast and the disclosure information of study authors, visit ASCO’s website about the 2020 Genitourinary Cancers Symposium. In order from the top, the abstract numbers are #TPS259, # TPS586, and #TPS7565. Disclosure information for this podcast’s speakers can be found in their individual biography, which can be found in the paragraph above.
Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.
Cancer.Net Podcasts are edited for content and length.